thioureidobutyronitrile
Trade name: Kevetrin
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01664000)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53ACTIVATOR
TP53 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-isothioureidobutyronitrile
- 4-isothioureidobutyronitrile
- kevetrin
- kevetrin
- kevetrin
- thioureidobutyronitrile
- thioureidobutyronitrile
- thioureidobutyronitrile
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03042702 | Phase 2 | Feb 9, 2017 | Innovation Pharmaceuticals |
| NCT01664000 | Phase 1 | Oct 1, 2012 | Harvard University, Innovation Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovation Pharmaceuticals | For profit | 2 | 2 | 2 | 2012 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1